=== PAGE 10 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Mandy Edwards
Mayne Pharma LLC
NDA 214154/ MA 107

Conclusion and Requested Action

For the reasons discussed above, the speaker deck misbrands Nextstellis within the meaning
of the FD&C Act and makes its distribution violative. 21 U.S.C. 352(a); 321(n); 331 (a). C.f.
21 CFR 202.1 (e)(3)(i); (e)(5).

This letter notifies you of our concerns and provides you with an opportunity to address them.
OPDP requests that Mayne cease any violations of the FD&C Act. Please submit a written
response to this letter within 15 working days from the date of receipt, addressing the
concerns described in this letter, listing all promotional communications (with the 2253
submission date) for Nextstellis that contain presentations like those described above, and
explaining your plan for the timely discontinuation of such communications, or for ceasing
distribution of Nextstellis.

If you believe that your products are not in violation of the FD&C Act, please include in your
submission to us your reasoning and any supporting information for our consideration within
15 working days from the date of receipt of this letter.

The concerns discussed in this letter do not necessarily constitute an exhaustive list of
potential violations. It is your responsibility to ensure compliance with each applicable
requirement of the FD&C Act and FDA implementing regulations.

Please direct your response to the undersigned at the **Food and Drug Administration,**
**Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-**
**B Ammendale Road, Beltsville, Maryland 20705-1266**. A courtesy copy can be sent by
facsimile to (301) 847-8444. Please refer to MA 107 in addition to the NDA number in all
future correspondence relating to this particular matter. All correspondence should include a
subject line that clearly identifies the submission as a Response to Untitled Letter. You are
encouraged, but not required, to submit your response in eCTD format. All correspondence
submitted in response to this letter should be placed under eCTD Heading 1.15.1.6.
Additionally, the response submission should be coded as an Amendment to eCTD
Sequence 0186 under NDA 214154. Questions related to the submission of your response
letter should be emailed to the OPDP RPM at CDER-OPDP-RPM@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

James Dvorsky, PharmD, MPH
Team Leader
Division of Advertising & Promotion Review 2
Office of Prescription Drug Promotion

Reference ID: 5580097
Page 10
